Johnson & Johnson

06/28/2024 | Press release | Distributed by Public on 06/28/2024 09:49

RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first line treatment of patients with advanced non[...]